GC022F / AstraZeneca, Gracell - LARVOL DELTA

Genetic diversity and population structure of the native grass carp (Ctenopharyngodon idella) from the Xiangjiang River revealed by microsatellite markers. (PubMed, J Fish Biol) - "Both unweighted pair group method with arithmetic mean (UPGMA) phylogenetic tree and principal coordinate analysis (PCoA) consistently showed a closer genetic relationship between GC2021 and GC2016, and a relatively more distant relationship for GC2017 and GC2022...Although some year-classes exhibited low NE values, the high gene flow among cohorts may mitigate associated inbreeding risk. These findings provide a scientific basis for the conservation and sustainable utilization of native Xiangjiang grass carp, with important implications for maintaining aquatic biodiversity in the Xiangjiang River and supporting the development of aquaculture industry."

Journal

[VIRTUAL] Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL) (ASH 2020) - P1 | "All patients received a conditioning regimen of IV fludarabine (25mg/m2/d) and cyclophosphamide (250mg/m2/d) for 3 days prior to GC022F infusion...Our clinical data demonstrate that GC022F is safe and efficacious in treating patients with CD19+CD22+ B-ALL. More data on additional patients and longer observation time are needed to further evaluate CD19/CD22 dual FasTCAR-T cell product."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • CCR7 • LAG3 • PD-1

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2; N=18; Not yet recruiting; Sponsor: He Huang

Clinical • New P1/2 trial • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Hebei Yanda Ludaopei Hospital

New P1 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology